The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
For full access to this article login to GEN Select now.
Cancer Marker Pursuit Heats Up
Field at Critical Juncture as Many Newly Characterized Biomarkers Show Promise
- The search for cancer biomarkers has proven to be a long, frustrating, and mainly fruitless exercise. Despite the substantial investment, no new markers suitable for large-scale screening protocols have achieved FDA approval. Yet, improvements in investigative tools, as well as innovative computer analysis, offer hope that the situation may ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.